27
Roche vs. Natco – Genus vs. Species Patent Dispute over Risdiplam
Spinal Muscular Atrophy (SMA) is a rare genetic disorder that causes progressive muscle weakness and wasting, impacting voluntary muscle movement. India sees 3,000 to 4,000 new SMA cases annually, given its birth rate of 25-27 million per year. Evrysdi (Risdiplam), developed by Roche, is a breakthrough oral therapy for SMA. It was approved in India […]